#### **ORDERING INFORMATION**



#### SPRAYSHIELD™ ADHESION BARRIER SYSTEM

Order Code:	Description:	Quantity:	
SP10S-01	10 mL polymer kit and Air Assisted Sprayer, sterile, single-use	1 kit/box	



## **COMPONENTS** - Also sold separately

## **POLYMER KIT**

Order Code:	Description:	Quantity:
SSK01	10 mL polymer kit	1 kit/box



#### **AIR ASSISTED SPRAYER**

Order Code:	Description:	Quantity:
AirSpray-01	Air Assisted Sprayer, 32 cm length, malleable shaft	1/box



#### FLOW REGULATOR - Sold separately

Order Code:	Description:	Quantity:
FR-6065	Nitrogen or air flow regulator for use in conjunction with Air Assisted Sprayer	1/box

For additional information, call your authorized SprayShield™ adhesion barrier system sales representative.

#### REFERENCES

- DeWilde RL, Trew GP, et al. Postoperative abdominal adhesions and their prevention in gynaecological surgery. Expert consensus position. Part 2—steps to reduce adhesion. Gynecol Surg 2007;4(4):243-253.
- 2. Seprafilm®\* Adhesion Barrier instructions for use. Genzyme Corporation.
- 3. ADEPT®\* Reduction Solution instructions for use. Baxter Healthcare Corporation.
- ETHICON Intercoat<sup>™</sup>\* brochure, 2007; Precautions. ETHICON Women's Health & Urology.
- 5. Ferland R, Campbell PK. Pre-clinical evaluation of a next-generation spray adhesion barrier for multiple site adhesion protection.
- 6. van Herendael BJ, et al. Abstract accepted for scientific presentation at European Society of Gynecologic Endoscopists Conference Oct 28-30, 2009; Florence 'Initial experience with a synthetic adhesion barrier SprayShield™ on fertility patients and pelvic pain patients—small prospective study including second look procedures.' Single investigator sponsored study, 16 patients (12 treated, 4 control).

SprayShield™ adhesion barrier system is not available for sale in the United States.

COVIDIEN, COVIDIEN with logo, Covidien logo and positive results for life are U.S. and/or internationally registered trademarks of Covidien AG. All other brands are trademarks of a Covidien company.


© 2009 Covidien.

12 09 P090319



COVIDIEN (UK)
LIMITED COMMERCIAL
154 FAREHAM ROAD
GOSPORT HAMPSHIRE
PO 13 OAS
UNITED KINGDOM (UK)

+44 (0) 1329 224226 [1 +44 (0) 1329 224334 [F WWW.COVIDIEN.CO
WWW.SPRAYSHIELDINFO.CO



# **SprayShield™ Adhesion Barrier System**

**Abdominopelvic Adhesion Protection** 





# SprayShield™ Adhesion Barrier System Easy to use, secure, persistent protection for multiple sites

The SprayShield™ adhesion barrier system is designed to address the limitations of other adhesion barriers.

#### **SECURE ADHERENCE**

The SprayShield™ system technology is a unique, synthetic hydrogel that:

- Polymerizes in seconds when sprayed
- Provides secure protection with sitespecific application
- Can be irrigated almost immediately

## **EASY TO USE ON COMPLEX ANATOMY**

The SprayShield<sup>™</sup> adhesion barrier system allows multiple-site abdominopelvic protection, even on complex anatomies:

- Can cover multiple adhesiogenic sites with just one kit
- A 32 cm sprayer shaft is designed for laparoscopic procedures
- A bendable tip applicator allows for rapid coverage of complex shapes

#### PERSISTENCE FROM 2-7 DAYS

The SprayShield<sup>™</sup> adhesion barrier system is designed to reduce adhesions for up to one week following surgery.


#### **EASY VISUALIZATION**

Colored blue, the hydrogel allows to easily assess coverage and thickness upon application.

#### THE COMPLETE SOLUTION: HOW THE SPRAYSHIELD™ SYSTEM COMPARES

Adhesion Barriers	Adherent to tissue	Site- specific	Easy to use with complex anatomy coverage	Can be irrigated	Easy to handle in open surgery and laparoscopy	Easy to visualize	Persists up to one week
SprayShield™ Adhesion Barrier	•	•	•	•	•	•	•
Hyaluronic acid- based resorbable knitting <sup>1,2</sup>							
Cellulose-based resorbable knitting <sup>1</sup>							
Solution of hydro-flotation 1,3			•			•	
Cellulose- based gel <sup>4</sup>	_				•		
Hyaluronic acid-based gel <sup>1,3</sup>					•		

## The next generation in protection against adhesions



In a GYN porcine model, the SprayShield<sup>™</sup> adhesion barrier system demonstrated a significant reduction in the extent (area) of adhesions. As compared with the control (good surgical technique), the SprayShield<sup>™</sup> adhesion barrier system demonstrated an 83% reduction in extent (area) of adhesions (p=0.012), a 47% reduction in incidence of post-op adhesions (p=0.04) and a 31% reduction in severity of adhesions.

# EVALUATION OF SPRAYSHIELD™ ADHESION BARRIER SYSTEM IN A PORCINE MODEL OF GYNECOLOGICAL SURGERY<sup>5</sup>

Eighteen (18) virgin hogs, randomized to control (good surgical technique) or adhesion barrier groups.

# EFFECTIVENESS, PERSISTENCE, COVERAGE OF COMPLEX ANATOMY AND EASE OF USE<sup>6</sup>


Early experience in a prospective study of 16 GYN patients with the SprayShield™ adhesion barrier system is providing positive results. This small, single-investigator study was sponsored by Covidien.

#### STUDY OVERVIEW

Study Group	Study procedure	SprayShield"- treated patients	Second-look laparoscopy	# application sites	Time of SprayShield <sup>™</sup> application	Outcomes
Group I	Laparoscopic myomectomy and tubal reanastomosis patients	3	2	1, 3 (1, 3 kits)	2, 7 m	No de novo adhesions
Group II	Laparoscopic endometriosis III	2	2	9 (1 kit)	3, 3 m	Limited reformation of adhesions where initial severe adhesions were not completely lysed
Group III	Laparoscopic adhesiolysis	7	0	5, 4 (1 kit)	3, 1 m	Second look not applicable

Outcomes were assessed in 4 patients with second-look laparoscopy.

## TUBAL REFERTILIZATION WITH SPRAYSHIELD™ ADHESION BARRIER SYSTEM




Initial




Second Look

#### **GROUP I DETAILED OUTCOMES<sup>6</sup>**



Outcomes included no de novo adhesions in the SprayShield™ group (n=2 SLL). In the control group (n=4 SLL\*), de novo adhesions formed at the surgical site, requiring an additional 9 minutes to lyse.

#### GROUP II DETAILED OUTCOMES<sup>6</sup>



Outcomes included limited reformation of lysed adhesions (n=2 SLL). In the second patient, 2 out of 7 initial severe adhesions were not completely lysed in the initial procedure, and they reformed back into 2 severe adhesions.

<sup>\*</sup>Prospective case matched controls